Assessing extracellular vesicle (EV) PD-L1 via liquid biopsy is an attractive non-invasive approach, but its predictive efficacy is confounded by non-tumor-derived EV background. To overcome this limitation, a novel assay selectively captured tumor-derived EVs (TEX) using the tumor-specific glycoantigen TF-Ag-α in serum from 91 NSCLC patients undergoing anti-PD-1 therapy. While baseline levels showed moderate performance (AUC 0.76), dynamic fold changes after the first treatment cycle revealed a ~4.18-fold increase in responders and a ~20% decrease in non-responders. This dynamic on-treatment metric delivered superior predictive power with an AUC of 0.93 (sensitivity 0.95, specificity 0.80), substantially outperforming both total EV PD-L1 and conventional tissue PD-L1.
Cervical adenocarcinoma is linked to poorer survival and reduced response to immunotherapy. This study identified STK11 alterations, including mutations and focal deletions, as a distinct feature of HPV-positive cervical adenocarcinomas, affecting 23% of these tumors. These alterations are associated with a younger age at diagnosis, poorer overall survival, and inferior outcomes following immune checkpoint inhibitor therapy. Comprehensive genomic analyses revealed complex structural rearrangements involving chromosome 19p and STK11. These findings define an aggressive molecular subgroup and have implications for molecular classification and future targeted therapeutic strategies.
This study investigates the interaction between mutated KRAS and AGO2 in colorectal cancer (CRC), a mechanism that impairs AGO2 function and promotes tumor progression. Researchers developed peptide-gold nanoparticles (Au-pep) to specifically disrupt this interaction, which restored microRNA expression, particularly let-7c-5p. This restoration led to the downregulation of key oncogenic drivers such as KRAS, c-Myc, and Bcl2, suppressing the growth of KRAS-mutated CRC cells and inducing apoptosis. Furthermore, this approach sensitized cells to existing treatments, including 5-fluorouracil and immunotherapy, by regulating ABCC5 and PD-L1.
This study performed integrated genomic, transcriptomic, and DNA methylation profiling on 76 desmoid tumors (DTs), uncovering frequent mutations in chromatin-remodeling genes, notably KMT2C, in addition to the known CTNNB1 and APC mutations. Transcriptomic analysis identified two robust molecular subtypes: immune-myogenic and mesenchymal-like. The immune-myogenic subtype exhibited high expression of myogenic markers and immune checkpoint genes, alongside enhancer hypomethylation. This subtype is associated with increased immune cell infiltration and predicts a higher responsiveness to immune checkpoint inhibitors.
This pooled analysis of two phase II clinical trials, MEDITREME and METIMMOX, investigated the efficacy of first-line chemoimmunotherapy in patients with microsatellite stable (MSS) metastatic colorectal cancer. The findings revealed a significant improvement in median overall survival for the chemoimmunotherapy group compared to chemotherapy alone. Additionally, higher complete response rates were observed with the combination therapy. The study also suggests that baseline CD8+ T-cell infiltration could serve as a predictive biomarker to identify patients most likely to benefit from this treatment approach.
This retrospective study analyzed 120 cases of lung adenocarcinoma (LUAD) with malignant serous effusions (MSE) to characterize their clinicopathologic, molecular, and prognostic features. Pleural effusions were most common, but pericardial involvement was associated with the shortest overall survival. Molecular profiling revealed TP53 mutations and actionable alterations in genes such as EGFR, KRAS, BRAF, ALK, and ROS1. NKX2-1 (TTF-1) negativity and the absence of actionable alterations were independent adverse prognostic factors, with dual NKX2-1/CD274 (PD-L1) negativity defining the poorest prognosis subgroup. Immunotherapy-based regimens and tyrosine kinase inhibitors showed varying survival benefits.